LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DuPont to Acquire Verdia Subsidiary of Maxygen

By Biotechdaily staff writers
Posted on 09 Jun 2004
To enhance its research and discovery capabilities, DuPont (Wilmington, DE, USA) has agreed to acquire Verdia, Inc. (Redwood City, CA, USA), a subsidiary of Maxygen, Inc. (also in Redwood City).

DuPont plans to purchase the plant sciences company for U.S.$64 million in cash. DuPont will have worldwide, royalty-free rights to use Maxygen's MolecularBreeding directed evolution platform, known as gene shuffling, for agricultural applications across its agriculture and nutrition platform. DuPont plans to retain Verdia's name.

Scientists at Verdia and another DuPont subsidiary, Pioneer Hi-Bred International, unveiled the first agricultural trait developed through gene shuffling in the May 21, 2004, issue of Science. Pioneer currently has this trait, glyphosate resistance, in field tests in corn and expects to have it on the market within the next five to six years. DuPont will be able to tap Verdia technology and expertise to improve plants' health benefits, nutritional value, and taste for the consumer market while also improving processing attributes for food manufacturers.

"Verdia will significantly enhance our gene research and trait discovery capabilities,” said Jim Miller, DuPont vice president, crop genetics research and development. "The technology should allow us to reach research targets up to three years faster and more efficiently.”




Related Links:
DuPont
Maxygen

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries



Sekisui Diagnostics UK Ltd.